MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Tax policy; LIFO-last-in, first-out; foreign earnings, corporate tax rate; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| DAMON SHELBY PORTER | — |
| PETER SLONE New | — |
Health Issues HCR
The Social Determinants Accelerator Act, S.4264; U.S. MADE Act of 2020, H.R. 6880; MADE in America Act, H.R.3; Oncology Care Model; Radiation Oncology APM; Lower Drug Costs Now Act of 2019, H.R.1845; Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R.748; CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution. H.R.2503 - The Social Determinants Accelerator Act of 2021, H.R.3 - Drug pricing and transparency, H.R.3, H.R.19; Budget Reconciliation; International price referencing, H.R.19; Medical Supplies for Pandemics Act of 2021, S.65; Improving Seniors Timely Access to Care Act, H.R. 3173; Safe Step Act, 2163; Buy America and domestic sourcing, strategic national stockpile H.R.3635; S.308; H.R.2780; global operations, trade; Opioids, substance abuse and prescription safety alert systems; Issues remain the same with addition of Build Back Better Act, H.R.5376; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| DAMON SHELBY PORTER | — |
| PETER SLONE | — |
Medicare/Medicaid MMM
Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution; H.R. 1868, Sequestration; H.R.2503; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| THOMAS BORCK | — |
| BEN JONES | — |
| LISA LANGENDERFER | — |
| DAMON SHELBY PORTER | — |
| PETER SLONE New | — |
Pharmacy PHA
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytic dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect remuneration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution; S.1362; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| THOMAS BORCK | — |
| BEN JONES | — |
| LISA LANGENDERFER | — |
| DAMON SHELBY PORTER | — |
| PETER SLONE New | — |
Tariff (miscellaneous tariff bills) TAR
Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| DAMON SHELBY PORTER | — |
| PETER SLONE New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.